BMC Women’s Health has retracted a prospective, double-blinded randomized trial evaluating platelet-rich plasma injections into the vaginal mucosa for vulvovaginal atrophy. Editors said they found major discrepancies between the trial’s clinical trial registration and the experimental procedures described in the manuscript. The retraction also cites unresolved concerns about the authenticity of statistical data, including numerical inconsistencies between reported means/standard deviations and the study’s tables and figures. The editorial board concluded it could no longer maintain confidence in the findings or conclusions. For biotech and clinical stakeholders, the case highlights the ongoing need for data integrity checks tied to study registration and transparent source records, especially in RCTs that influence clinical adoption of procedure-based therapies.
Get the Daily Brief